CD7

Orphan designation: anti-CD3 mAb (SPV-T3a)-ricin A chain fusion protein,anti-CD7 mAb (WT1)-ricin A chain fusion protein Treatment of graft-versus-host disease, 26/08/2005 Positive

Retrieved on: 
Thursday, April 18, 2024
Community, Eurostat, Civil service commission, Diagnosis, CD7, Graft-versus-host disease, Cell, Bone marrow, Disease, Patient, Committee, Extrapyramidal system, Tissue, Knowledge, Antibody, Regulation, EMA, IRIS, Protein, CD3, BV, European, Skin, WT1, COMP, Oxygen, Immune system, European Commission, Safety, Hematopoietic stem cell transplantation, Stomach, Liver, Pharmaceutical industry

Orphan designation: anti-CD3 mAb (SPV-T3a)-ricin A chain fusion protein,anti-CD7 mAb (WT1)-ricin A chain fusion protein Treatment of graft-versus-host disease, 26/08/2005 Positive

Key Points: 


Orphan designation: anti-CD3 mAb (SPV-T3a)-ricin A chain fusion protein,anti-CD7 mAb (WT1)-ricin A chain fusion protein Treatment of graft-versus-host disease, 26/08/2005 Positive

Antion Biosciences announces latest data and validation of its technology platform through important milestone achievements

Retrieved on: 
Wednesday, March 6, 2024
Engineering, Doctor of Philosophy, CAR7, Research and development, Chromosome, Kite Pharma, CD7, Cell, Risk, MicroRNA, Safety, History, Malignancy, Patient, Development, Partnership, Vaccine

“miCAR7 is the product of thoughtful design and remarkable engineering,” commented Dr. Marco Alessandrini, PhD, Chief Executive Officer of Antion.

Key Points: 
  • “miCAR7 is the product of thoughtful design and remarkable engineering,” commented Dr. Marco Alessandrini, PhD, Chief Executive Officer of Antion.
  • Proof-of-Concept data for miCAR7 was unveiled for the first time at the 7th CAR-TCR Summit in London on February 28th, 2024.
  • In August of 2023, Antion successfully delivered novel gene constructs and a supporting data package for silencing of four relevant targets to Allogene.
  • With a validated technology platform, established operations and a history of fruitful collaboration, Antion is optimally positioned to accelerate its pipeline developments, while leveraging the full potential of its technology through key strategic partnerships with global innovation leaders.

MaxCyte and Wugen Sign Strategic Platform License to Expedite Scale-Up of Clinical and Commercial Manufacturing of Wugen’s Investigational Allogeneic, Off-the-Shelf Cell Therapies for Cancers

Retrieved on: 
Tuesday, January 30, 2024
Partnership, Cell engineering, LBL, Orphan drug, Expert, NK, Patient, Transfection, Adolescence, NCT, MBA, Food, Cancer, CD7, Doctor of Philosophy, SPL, Pharmaceutical industry

Under the terms of the agreement, Wugen gains non-exclusive clinical and commercial rights to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform.

Key Points: 
  • Under the terms of the agreement, Wugen gains non-exclusive clinical and commercial rights to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform.
  • Wugen is developing the next generation of off-the-shelf memory natural killer (NK) and CAR-T cell therapies for cancer.
  • The company’s investigational cell therapies originate from healthy donors and are further engineered to enhance their function of eliminating cancer cells.
  • Wugen is MaxCyte’s 26th clinical/commercial partnership overall, each of which generates pre-commercial milestone revenue, the vast majority of which includes sales-based payments.

Beam Therapeutics Reports Progress Across Base Editing Portfolio and Outlines Key Anticipated Milestones

Retrieved on: 
Monday, January 9, 2023
IND, Disease, Pizzicato, Cell, Blood, Toxicity, Thalassemia, Tissue, HSC, Biotechnology, Fetal hemoglobin, LNP, Safety, Glucose, FDA, SCD, Mutation, Security, Starch, Gene editing, Toxic epidermal necrolysis, ASH, Conference, CD7, Immune system, Patient, G6PC, Research, Cancer, Clinical trial, Hematology, Science, Liver, Society, Sickle cell disease, AATD, Investment, Genetic disorder, ESCAPE, Pharmaceutical industry, Vaccine, Medical imaging, Beam

“Beam enters 2023 with significant momentum across all of our core pipeline areas and an expanding leadership position in the next generation of gene editing,” said John Evans, chief executive officer of Beam.

Key Points: 
  • “Beam enters 2023 with significant momentum across all of our core pipeline areas and an expanding leadership position in the next generation of gene editing,” said John Evans, chief executive officer of Beam.
  • Platform Opportunity: Beam is advancing its Engineered Stem Cell Antibody Paired Evasion (ESCAPE) conditioning strategy in an effort to bring base editing treatments to more patients.
  • In December 2022, Beam presented in vivo proof-of-concept data at the American Society of Hematology Annual Meeting and Exposition (ASH) highlighting its potential.
  • BEAM-201: In December 2022, Beam received clearance from the FDA for its Investigational New Drug (IND) application for BEAM-201.

Wugen Receives U.S. FDA Fast Track and Rare Pediatric Disease Designations for WU-CART-007 for the Treatment of R/R T-ALL/LBL

Retrieved on: 
Tuesday, July 19, 2022
Research, FDA, Clinical Trials, Health Technology, Biotechnology, Pharmaceutical, Health, Science, Oncology, Other Science, LBL, CIML, Graft-versus-host disease, Cancer, Patient, Lymphatic system, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, NCT, Phenotype, Safety, CRISPR, Review, Food, Technology, Risk, CD7, Degenerative disease, NK, FDA, TRAC, Priority review, Pharmaceutical industry, Medical device, Vaccine

WU-CART-007 is currently being explored for the treatment of relapsed or refractory (R/R) T-cell acute lymphoblastic leukemia (T-ALL)/lymphoblastic lymphoma (LBL).

Key Points: 
  • WU-CART-007 is currently being explored for the treatment of relapsed or refractory (R/R) T-cell acute lymphoblastic leukemia (T-ALL)/lymphoblastic lymphoma (LBL).
  • We are very pleased to have received both fast track and rare pediatric disease designations, which re-affirm the great unmet need for new treatment options for people with R/R T-ALL/LBL, said Dan Kemp, Ph.D., President and Chief Executive Officer of Wugen.
  • We look forward to working closely with the FDA as we continue to advance WU-CART-007 through clinical development.
  • Features of Fast Track Designation include opportunities for more frequent interactions with the FDA review team and, if supported by clinical data, eligibility for Priority Review.

Gracell Biotechnologies Reports First Quarter 2022 Unaudited Financial Results and Provides Corporate Update

Retrieved on: 
Monday, May 16, 2022
DL2, Research, U.S. Securities and Exchange Commission, Webcast, EHA, Conference, Private Securities Litigation Reform Act, CAR, Cancer, Income, RMB, Lymphoid leukemia, IIT, Investment, Federal Reserve Board of Governors, CD7, HVG, ADS, SAN, NK, Form 20-F, Graceling, BCMA, GLOBE, Company, Holm–Bonferroni method, Gene editing, Efficiency, ASCO, CD19, Security (finance), Persephone Borrow, B-ALL, Annual report, Patient, NASDAQ, AACR, TME, RRMM, Translation, Graft-versus-host disease, Technology, Industry, SMART, CEO, Medical device, Pharmaceutical industry, Vaccine, Renewable energy, Online gambling, Broadcasting, Mobile phone, Renminbi, IND

ET today

Key Points: 
  • ET today
    SAN DIEGO, Calif. and SUZHOU and SHANGHAI, China, May 16, 2022 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (Gracell or Company), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, today reported first quarter unaudited financial results for the three months ended March 31, 2022, and provided corporate updates.
  • Plan to submit the U.S. and China IND filings for RRMM in the second half of 2022.
  • First-in-human data from China IIT study in B-ALL patients were presented at AACR on April 12, 2022.
  • Gracell specifically disclaims any obligation to update any forward-looking statement, whether due to new information, future events, or otherwise.

Gracell Biotechnologies to Present Clinical Data on BCMA/CD19 Dual-targeting CAR-T GC012F in RRMM and B-NHL and CD19/CD7 Dual-directed Allogeneic CAR-T GC502 in B-ALL at EHA2022 Congress

Retrieved on: 
Thursday, May 12, 2022
DL2, U.S. Securities and Exchange Commission, Private Securities Litigation Reform Act, CAR, Cancer, Risk, Lymphoid leukemia, Toxic epidermal necrolysis, IIT, CD7, NHL, HVG, SAN, NK, Form 20-F, Acute lymphoblastic leukemia, BCMA, Non-Hodgkin lymphoma, CT, Degenerative disease, 2021 Essex County Council election, Patient, Bone marrow, Gene editing, Cytokine release syndrome, HLA, Efficiency, Lymphatic system, First grade, European Hematology Association, Congress, ASCO, ALL, LinkedIn, CD19, Security (finance), Multiple myeloma, B-ALL, Annual report, NASDAQ, RRMM, Graft-versus-host disease, Industry, SMART, Safety, CRS, T-ALL, Lymphocyte, Pharmaceutical industry, Vaccine, Medical imaging, Fashion, Graceling, Indian Institutes of Technology

"The new data, including the expanded indication of GC012F into B-NHL, demonstrates the potential of our platforms and provides further validation.

Key Points: 
  • "The new data, including the expanded indication of GC012F into B-NHL, demonstrates the potential of our platforms and provides further validation.
  • The CD19/CD7 dual-directed CAR-T therapy GC502 is our second allogeneic candidate on our TruUCAR platform, demonstrating the potential wide applicability of the TruUCAR design."
  • Gracell will present the early results of the first-in-human phase 1 IIT in China evaluating the safety and tolerability of GC012F in B-NHL patients.
  • Three patients who had received a median of two prior lines of therapy were enrolled, all of which presented with bulky disease.

KIOXIA America Showcases Breakthrough Flash Storage Solutions at Dell Technologies World

Retrieved on: 
Thursday, April 28, 2022
Networks, Hardware, Data Management, Technology, Software, Diamond, PCI Express, Solution, DNA, Artificial intelligence, LinkedIn, NVM Express, Name, Dell PowerEdge, SATA, Multimedia, Marketing, Personal computer, PCI-SIG, Solid-state drive, Software, SSD, RM6, MB, VMware, NVM, SED, Interview, Technology, Dell Technologies, CM6, BICS, SAS, Enterprise, OLTP, DRAM, Data center, 3D, TB, Dell, MongoDB, CD7, Resort, TLC, EDSFF, Aerospike, Culture, Computer data storage, Video game console, Public relations, Payment card, Kerosene

View the full release here: https://www.businesswire.com/news/home/20220428005207/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20220428005207/en/
    At Dell Technologies World, KIOXIA will demonstrate how its innovative SSDs are accelerating customer application performance and enabling product breakthroughs.
  • On May 3rd at 1:30pm and May 4th at 10am, KIOXIA America and Dell will jointly conduct a session titled, KIOXIA and Dell: Together on the Forefront of Storage Technology.
  • The breakout session and interview will be available on the KIOXIA Dell Technologies World sponsor page and can also be viewed on the Dell Technologies World website at the conclusion of the show.
  • KIOXIA has been a Dell strategic supplier for two decades and a Diamond-level Dell Technologies World sponsor for multiple years.

Gracell Biotechnologies to Present Data at AACR Annual Meeting 2022 Showcasing Early First-in-Human Results for GC502 in r/r B-ALL

Retrieved on: 
Friday, April 8, 2022
Online, B-ALL, LinkedIn, PALO, Form 20-F, NASDAQ, Private Securities Litigation Reform Act, DL2, Degenerative disease, Trial of the century, Lymphocyte, SMART, Cytokine release syndrome, Annual report, CRS, Bone marrow, CAR, AACR, Risk, American Association, Patient, Holm–Bonferroni method, Cancer, HVG, U.S. Securities and Exchange Commission, CD7, ALL, Lymphoid leukemia, Association, American Association for Cancer Research, Gene editing, Industry, Graft-versus-host disease, CD19, HLA, Acute lymphoblastic leukemia, IIT, Lymphatic system, T-ALL, Security (finance), Pharmaceutical industry, Vaccine, Graceling

PALO ALTO, Calif. and SUZHOU, China, April 8, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced the early results of a first-in-human clinical study of GC502, an allogeneic CD19/CD7 dual-directed chimeric antigen receptor (CAR) T cell therapy for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL). Gracell will share the data in a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2022 on April 12.

Key Points: 
  • Gracell will share the data in a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2022 on April 12.
  • "We are very excited to present our data on GC502 at this year's AACR annual meeting.
  • CD19 is a validated target in the treatment of r/r B-ALL," said Dr. Martina Sersch, Chief Medical Officer of Gracell.
  • The early results show the potential of GC502 and warrant further evaluation in the ongoing clinical investigator-initiated-trial (IIT).

Wugen Announces First Patient Dosed in Phase 1/2 Trial of WU-CART-007 for the Treatment of Patients with R/R T-ALL/LBL

Retrieved on: 
Tuesday, March 15, 2022
Research, Finance, Clinical Trials, Professional Services, Biotechnology, Health, Pharmaceutical, Science, Oncology, DOR, ODD, TRAC, T-cell acute lymphoblastic leukemia, Technology, Associate, Patient, Prescription Drug User Fee Act, NK, FDA, T-ALL, Orphan Drug Act of 1983, Acute lymphoblastic leukemia, Risk, Lymphatic system, Safety, Acute leukemia, Oncology, George Washington University School of Medicine & Health Sciences, Cancer, Infection, Food, ORR, NCT, Population, Graft-versus-host disease, Division, CD7, AML, PDUFA, LBL, CRISPR, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Disease, Marketing, Pharmaceutical industry, Vaccine, WU-CART-007, Wugen, WU-CART-007, WUGEN

Additionally, Wugen announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to WU-CART-007 for the treatment of acute lymphoblastic leukemia.

Key Points: 
  • Additionally, Wugen announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to WU-CART-007 for the treatment of acute lymphoblastic leukemia.
  • We look forward to advancing WU-CART-007, which has the potential to transform the care paradigm for these patients.
  • The Phase 1/2 trial is a first-in-human, multi-site, global, open-label study of WU-CART-007 to evaluate its safety and clinical efficacy in patients with R/R T-ALL/LBL.
  • WU-CART-007 is currently being evaluated in a global Phase 1/2 clinical trial for the treatment of relapsed or refractory (R/R) T-cell acute lymphoblastic leukemia (T-ALL)/lymphoblastic lymphoma (LBL).